Psilocybin law in Georgia

Scheduling

Psilocybin and psilocyn are listed in Schedule I, O.C.G.A. 16-13-25(3)(N) and (O). [Georgia Code 16-13-25, Schedule I (current as of March 28, 2024), FindLaw (reproduction of Official Code of Georgia), 2024-03-28, read 26 October 2026] [HB 382 bill text (LC 33 9773), Georgia General Assembly, 2025, read 26 October 2026]

What the law says

• HB 382 (Act 476), signed 11 May 2026 and effective 1 July 2026, excludes FDA-approved drugs containing crystalline polymorph psilocybin from the Schedule I definition of psilocybin, so such a drug would follow its federal DEA scheduling. [HB 382 (2025-2026), Controlled substances; Schedule I; psilocybin; revise a provision, Georgia General Assembly, 2026-05-11, read 26 October 2026] [HB 382 bill text (LC 33 9773), Georgia General Assembly, 2025, read 26 October 2026]
• HB 717 (Act 634), signed 12 May 2026 and effective 1 July 2026, directs the Georgia Composite Medical Board to regulate and license clinics that administer psychedelic-assisted treatment and therapy. [HB 717 (2025-2026), Medical Practice Act; regulation of the administration of psychedelic-assisted treatment and therapy, Georgia General Assembly, 2026-05-12, read 26 October 2026]
• Under HB 717 the Medical Board must issue clinic rules by 31 December 2026 and clinics must be licensed by 1 July 2027; the definition covers treatments such as IV ketamine infusions. [Georgia Enacts Regulations for Psychedelic Clinics, Healthesystems, 2026-05-25, read 26 October 2026]

Penalties

• Possessing a Schedule I controlled substance is a felony; if the aggregate weight is less than one gram of a solid (or less than one milliliter of a liquid), the penalty is imprisonment for one to three years (O.C.G.A. 16-13-30(a) and (c)(1)). [Georgia Code 16-13-30 (current as of March 28, 2024), FindLaw (reproduction of Official Code of Georgia), 2024-03-28, read 26 October 2026]

Bills

• HB 382 2025-2026

  Controlled substances; Schedule I; psilocybin; revise a provision

  Carves FDA-approved crystalline polymorph psilocybin drugs out of Schedule I so they follow DEA scheduling.

  Status: Signed 11 May 2026 (Act 476), effective 1 July 2026, 11 May 2026

• HB 717 2025-2026

  Medical Practice Act; regulation of the administration of psychedelic-assisted treatment and therapy

  Requires Medical Board rules and licensure for clinics providing psychedelic-assisted treatment and therapy.

  Status: Signed 12 May 2026 (Act 634), effective 1 July 2026, 12 May 2026

• HB 1296 2025-2026

  Mental health; pilot program to support clinical research of certain veterans and first responders suffering from certain conditions

  Would have created a pilot program to support clinical research of breakthrough treatments for veterans and first responders.

  Status: Passed House; read and referred in Senate 6 March 2026; died at end of 2025-2026 session, 6 March 2026

• SB 631 2025-2026

  Veterans Mental Health Innovations Act

  Would have authorized state grants for FDA-approved ibogaine clinical trials for veterans.

  Status: Read and referred to Senate Health and Human Services 25 March 2026; died at end of 2025-2026 session, 25 March 2026

Dated changes

• 12 May 2026: Requires Medical Board rules and licensure for clinics providing psychedelic-assisted treatment and therapy. Status: Signed 12 May 2026 (Act 634), effective 1 July 2026. Source
• 11 May 2026: Carves FDA-approved crystalline polymorph psilocybin drugs out of Schedule I so they follow DEA scheduling. Status: Signed 11 May 2026 (Act 476), effective 1 July 2026. Source